联合使用5%匹马霉素和2%益康唑治疗真菌性角膜炎。
Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis.
作者信息
Prajna N Venkatesh, Nirmalan Praveen K, Mahalakshmi Rajendran, Lalitha Prajna, Srinivasan Muthiah
机构信息
Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India.
出版信息
Cornea. 2004 Nov;23(8):793-6. doi: 10.1097/01.ico.0000134193.64357.82.
PURPOSE
To determine if concurrent use of 5% natamycin and 2% econazole offers greater benefits than monotherapy with 5% natamycin for the management of fungal keratitis.
METHODS
Subjects presenting to the cornea service were treated with 5% natamycin and 2% econazole used concurrently. We compared the results with a historical control of patients treated with 5% natamycin in the same calendar year. The same clinical and examination protocol including inclusion and exclusion criteria was used for both groups.
RESULTS
We compared results of 47 subjects on concurrent use of 5% natamycin and 2% econazole with all 53 subjects who had received 5% natamycin in a previous study (historical controls). Baseline characteristics were similar between the 2 groups. There were no significant differences (P=0.9) between the 2 arms for success (defined as a healed or healing ulcer).
CONCLUSIONS
Concurrent use of 5% natamycin and 2% econazole does not appear to offer additional benefits over monotherapy with 5% natamycin for the management of fungal keratitis.
目的
确定5%匹马霉素与2%益康唑联合使用在治疗真菌性角膜炎方面是否比单独使用5%匹马霉素具有更大的益处。
方法
到角膜科就诊的受试者接受5%匹马霉素与2%益康唑联合治疗。我们将结果与同一年接受5%匹马霉素治疗的患者的历史对照进行比较。两组采用相同的临床和检查方案，包括纳入和排除标准。
结果
我们将47例同时使用5%匹马霉素和2%益康唑的受试者的结果与之前一项研究中接受5%匹马霉素治疗的所有53例受试者（历史对照）进行了比较。两组的基线特征相似。两组在成功（定义为溃疡愈合或正在愈合）方面无显著差异（P = 0.9）。
结论
在治疗真菌性角膜炎方面，5%匹马霉素与2%益康唑联合使用似乎并不比单独使用5%匹马霉素具有更多益处。
Zotero 插件